Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Diego Centonze(University of Rome Tor Vergata), Massimo Filippi(Vita-Salute San Raffaele University), Melinda Magyari(University of Copenhagen), María Trojano(University of Bari Aldo Moro), Claudio Gasperini(Nini Hospital), Heinz Wiendl(University Medical Center Freiburg), Ludwig Kappos(University Hospital of Basel), Maria A. Rocca(Vita-Salute San Raffaele University), Celia Oreja‐Guevara, Hans-Peter Hartung(The University of Sydney)
Cited by 55
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k